|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
188,370,000 |
Market
Cap: |
16.70(B) |
Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
52
Week Range: |
$76.22 - $99 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 1018 |
Guru Rank Value : 0.1 |
Guru Occurances : 4 |
|
|
|
|
|
|
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
3,625 |
Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
714 |
160,302 |
276,407 |
571,147 |
Total Sell Value |
$64,260 |
$13,335,112 |
$23,824,420 |
$53,365,721 |
Total People Sold |
1 |
5 |
6 |
7 |
Total Sell Transactions |
1 |
11 |
22 |
49 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Grey Michael G |
Director |
|
2008-03-05 |
4 |
S |
$38.03 |
$820,682 |
D/D |
(21,500) |
8,500 |
|
- |
|
Grey Michael G |
Director |
|
2008-03-05 |
4 |
OE |
$10.33 |
$309,900 |
D/D |
30,000 |
30,000 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2008-03-04 |
4 |
S |
$38.00 |
$152,000 |
D/D |
(4,000) |
7,213 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2008-03-04 |
4 |
OE |
$6.46 |
$25,840 |
D/D |
4,000 |
31,213 |
|
- |
|
Klein Joseph III |
Director |
|
2008-03-03 |
4 |
S |
$38.00 |
$380,333 |
D/D |
(10,000) |
30,000 |
|
- |
|
Klein Joseph III |
Director |
|
2008-03-03 |
4/A |
S |
$37.80 |
$758,333 |
D/D |
(20,000) |
20,000 |
|
- |
|
Heron Elaine J |
Director |
|
2008-03-03 |
4 |
S |
$38.47 |
$769,400 |
D/D |
(20,000) |
0 |
|
- |
|
Davis George Eric |
VP, General Counsel |
|
2008-03-03 |
4 |
S |
$38.00 |
$760,000 |
D/D |
(20,000) |
3,397 |
|
- |
|
Davis George Eric |
VP, General Counsel |
|
2008-03-03 |
4 |
OE |
$6.13 |
$149,960 |
D/D |
20,000 |
23,397 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2008-03-03 |
4 |
S |
$38.10 |
$76,239 |
D/D |
(2,000) |
11,213 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2008-03-03 |
4 |
OE |
$6.46 |
$12,920 |
D/D |
2,000 |
27,213 |
|
- |
|
Aselage Steve |
SVP, Global Commercial Dev |
|
2008-03-03 |
4 |
S |
$38.00 |
$1,520,000 |
D/D |
(40,000) |
32,034 |
|
- |
|
Aselage Steve |
SVP, Global Commercial Dev |
|
2008-03-03 |
4 |
OE |
$7.16 |
$593,640 |
D/D |
65,000 |
72,034 |
|
- |
|
Klein Joseph III |
Director |
|
2008-02-29 |
4 |
OE |
$14.21 |
$426,300 |
D/D |
30,000 |
40,000 |
|
- |
|
Cooper Jeffrey H |
SVP, Chief Financial Officer |
|
2008-02-29 |
4 |
S |
$37.82 |
$224,058 |
D/D |
(5,905) |
1,005 |
|
- |
|
Lapalme Pierre |
Director |
|
2008-02-29 |
4 |
S |
$37.53 |
$341,101 |
D/D |
(9,025) |
12,575 |
|
- |
|
Lapalme Pierre |
Director |
|
2008-02-29 |
4 |
OE |
$5.92 |
$88,800 |
D/D |
15,000 |
21,600 |
|
- |
|
Klein Joseph III |
Director |
|
2008-02-29 |
4/A |
OE |
$14.21 |
$426,300 |
D/D |
30,000 |
40,000 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2008-02-29 |
4 |
S |
$37.91 |
$805,798 |
D/D |
(21,142) |
4,071 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2008-02-29 |
4 |
OE |
$6.46 |
$116,280 |
D/D |
18,000 |
25,213 |
|
- |
|
Lapalme Pierre |
Director |
|
2008-02-29 |
4 |
S |
$38.06 |
$229,615 |
D/D |
(5,975) |
6,600 |
|
- |
|
Cooper Jeffrey H |
SVP, Chief Financial Officer |
|
2008-02-29 |
4 |
S |
$37.53 |
$1,870,362 |
D/D |
(49,720) |
6,910 |
|
- |
|
Cooper Jeffrey H |
SVP, Chief Financial Officer |
|
2008-02-29 |
4 |
OE |
$5.15 |
$520,873 |
D/D |
55,625 |
56,630 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2008-02-21 |
4 |
AS |
$35.93 |
$109,010 |
D/D |
(2,990) |
0 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2008-02-21 |
4 |
OE |
$6.13 |
$40,350 |
D/D |
2,990 |
2,990 |
|
- |
|
1213 Records found
|
|
Page 41 of 49 |
|
|